<div id="readability-page-1"><p>Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of &#34;Buy&#34; from the ten ratings firms that are presently  covering the firm, Marketbeat reports. One analyst  has rated the stock with a sell rating, seven have given a buy rating and two have assigned  a strong buy rating to  the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.4444.</p><div><p><span></span><span>Get <strong>Trevi Therapeutics</strong> alerts:</span></p></div><p>Several brokerages have recently weighed in on TRVI. B. Riley raised shares of Trevi Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, November 17th. Oppenheimer increased their target price on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, November 14th. Morgan Stanley raised their target price on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, November 14th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. Finally, D. Boral Capital  reissued a &#34;buy&#34; rating and set a $19.00 price target on shares of Trevi Therapeutics in a research report on Friday, November 14th.</p><p><b>Check Out Our Latest Stock Analysis on TRVI</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds have recently bought and sold shares of TRVI. Russell Investments Group Ltd. raised its stake in shares of  Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock worth $25,000 after purchasing an additional 2,996 shares in the last quarter.  BIT Capital GmbH raised its position in  Trevi Therapeutics by 32.0% during the third quarter. BIT Capital GmbH now owns 6,739 shares of the company's stock worth $62,000 after acquiring an additional 1,633 shares in the last quarter.  Ameritas Investment Partners Inc. raised its position in  Trevi Therapeutics by 20.5% during the third quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after acquiring an additional 1,300 shares in the last quarter.  Strs Ohio acquired a new stake in  Trevi Therapeutics in the first quarter valued at $52,000.  Finally, AlphaQuest LLC acquired a new stake in  Trevi Therapeutics in the third quarter valued at $80,000. 95.76% of the stock is currently owned by institutional investors. </p><h2>Trevi Therapeutics Trading Down 2.4%</h2><p>TRVI stock opened at $12.11 on Thursday. The stock has a 50-day moving average price of $11.61 and a two-hundred day moving average price of $8.81. Trevi Therapeutics has a 1 year low of $3.47 and a 1 year high of $14.39. The stock has a market cap of $1.55 billion, a PE ratio of -32.73 and a beta of 0.83. </p><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.  On average, analysts forecast that  Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year. </p><h2>Trevi Therapeutics Company Profile</h2> (Get Free Report)<p>Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Trevi Therapeutics</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>How to Evaluate a Stock Before Buying </li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TRVI

<p>Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received a consensus "Buy" rating from analysts, with one sell, seven buy, and two strong buy ratings. The average 1-year price target is $21.44. Recent analyst actions include B. Riley's strong-buy rating and Oppenheimer's target price increase to $24.00. Institutional investors own 95.76% of the stock, which recently traded down 2.4% to $12.11.</p>

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts